DOCSLIB.ORG

Introduction to Opioids/Opiates

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Introduction to Opioids/Opiates Learning Objectives: After studying the material of this lecture, the student should: 1. Be able to list the precursors of the endogenous Introduction to opioids and the opioid receptors with which the endogenous opioids interact. Opioids/Opiates 2. Know the effects mediated by the interaction of opioids with each of the specific opioid receptors. 3. Learn the mechanism of the analgesic action of morphine. Sandra Welch, Ph.D. 4. Know the similarities and differences in the profile of Professor, Pharmacology and Toxicology clinically observed effects of the opioids. McGuire Hall 305, 828-8424, [email protected] 5. Understand the clinical signs associated with opiate overdose and with opiate withdrawal and the therapies used for each condition. 6. Know the most common drugs used in the maintenance of opiate abstinence. 7. Understand therapeutic precautions when administering opiates. NOTE: ALL TESTS WILL USE ONLY GENERIC NAMES OF DRUGS. ANY TERM IN BOLD OR UNDERLINED IS ABSOLUTELY REQUIRED INFORMATION FOR TESTING. ALL DIAGRAMS ARE REQUIRED INFORMATION FOR TESTING. 1 opium morphine narcotine codeine thebaine papaverine narceine opium opium morphine morphine narcotine narcotine codeine codeine thebaine thebaine papaverine papaverine narceine narceine DIACETYLMORPHINE heroin I. TERMINOLOGY A. Narcotics “Narcosis" = sleep II. HISTORY Legalistic term, proper pharmacological term is “Opioid Analgesics” B. Opium 1806 - Serturner - isolated morphine extract of opium poppy 1832 - Robiquet - isolated codeine C. Opiates 1951 - Nalorphine- the first opiate antagonist drugs derived from opium. Examples are and treatment for overdose morphine, codeine. 1967 - William R. Martin first described opiate D. Opioids receptor subtypes any drug or peptide that has opiate-like effects via binding to opiate receptors. Examples are the endogenous opioids. 2 Lots of things can modify pain sensitivity III. ENDOGENOUS OPIOIDS Figure 1. Schematic representation of the structures of the protein precursors of the three families of opioid peptides. i.e. those opioid peptides which occur naturally in the body Abbreviations: ENK - enkephalin; DYN = dynorphin; END = endorphin. The sequence of met- enkephalin is Tyr-Gly-Gly-Phe-Met, while that of leu-enkephalin is Tyr-Gly-Gly-Phe-Leu. A. Beta-Endorphin (modified from Akil et al., 1984) γ -MSH Goldstein, 1975 ACTH β -LPH 31 amino acids α -LPH β -END pituitary/hypothalamus/adrenal B. Met-Enkephalin α -MSH β -MSH MET-ENK Hughes and Kosterlitz, 1975 MET-ENK LEU-ENK Leu-Enkephalin Hughes and Kosterlitz, 1975 5 amino acids MET-ENK MET-ENK ARG 6 -GLY 7 -LEU 8 ARG 6 -PHE 7 C. Dynorphin important in modulation of analgesia LEU-ENK D. Orphanin FQ -- anti-analgesic α -NEOENDORPHIN E. Endomorphins 1 and 2 -- mu receptor endogenous ligands - DYN DYN A B analgesic β -NEOENDORPHIN Figure 1. Schematic representation of the structures of the protein Four genes are involved: precursors of the three families of opioid peptides. 1. Pro-opiomelanocortin Abbreviations: ENK - enkephalin; DYN = dynorphin; END = endorphin. The sequence of met- enkephalin is Tyr-Gly-Gly-Phe-Met, while that of leu-enkephalin is Tyr-Gly-Gly-Phe-Leu. (modified from Akil et al., 1984) γ -MSH ACTH β -LPH 2. Proenkephalin α -LPH β -END 3. Prodynorphin α -MSH β -MSH MET-ENK MET-ENK LEU-ENK 4. Pronociceptin/orphanin FQ MET-ENK MET-ENK ARG 6 -GLY 7 -LEU 8 ARG 6 -PHE 7 LEU-ENK α -NEOENDORPHIN DYN DYN A B β -NEOENDORPHIN 3 Figure 1. Schematic representation of the structures of the protein precursors of the three families of opioid peptides. Abbreviations: ENK - enkephalin; DYN = dynorphin; END = endorphin. The sequence of met- enkephalin is Tyr-Gly-Gly-Phe-Met, while that of leu-enkephalin is Tyr-Gly-Gly-Phe-Leu. (modified from Akil et al., 1984) γ -MSH ACTH β -LPH α -LPH β -END α -MSH β -MSH MET-ENK MET-ENK LEU-ENK MET-ENK MET-ENK ARG 6 -GLY 7 -LEU 8 ARG 6 -PHE 7 LEU-ENK α -NEOENDORPHIN DYN DYN A B β -NEOENDORPHIN Figure 1. Schematic representation of the structures of the protein precursors of the three families of opioid peptides. Abbreviations: ENK - enkephalin; DYN = dynorphin; END = endorphin. The sequence of met- enkephalin is Tyr-Gly-Gly-Phe-Met, while that of leu-enkephalin is Tyr-Gly-Gly-Phe-Leu. (modified from Akil et al., 1984) γ -MSH ACTH β -LPH α -LPH β -END α -MSH β -MSH MET-ENK MET-ENK LEU-ENK MET-ENK MET-ENK ARG 6 -GLY 7 -LEU 8 ARG 6 -PHE 7 LEU-ENK α -NEOENDORPHIN DYN DYN A B β -NEOENDORPHIN NEW “KIDS” ON THE BLOCK ! D. Orphanin FQ -- anti-analgesic E. Endomorphins 1 and 2 - mu receptor endogenous ligands - analgesic 4 MU1 endomorphins-endogenous ligands MU2 AGONISTS: morphine Agonists: Same as Table 1. Multiple Opiate Receptors codeine MU1 (mu, delta, and kappa opioid receptors meperidine fentanyl Antagonists: Same have been cloned) methadone as MU1 propoxyphene oxycodone tramadol EFFECTS: ANTAGONISTS: Respiratory Naloxone depression Naltrexone (medulla) EFFECTS: Analgesia Bradycardia Euphoria Physical dependence KAPPA 1,2,3 Dynorphins - endogenous ligands AGONISTS SIGMA Pentazocine Butorphanol NOT an opioid receptor ANTAGONISTS EFFECTS Naloxone* Naltrexone* Dysphoria *(much higher doses needed for antagonism, compared to Mydriasis the mu receptor) Hallucinations EFFECTS Miosis Sedation Spinal Analgesia DELTA 1&2 Met and Leu Enkephalin - Endogenous ligands EPSILON AGONISTS: ALL MU AGONISTS ALSO ACT AT DELTA RECEPTORS Beta-endorphin - Endogenous ligand NO SPECIFIC DELTA AGONISTS AVAILABLE FOR CLINICAL USE Effects similar to Mu1 ANTAGONISTS Naloxone Naltrexone EFFECTS Spinal analgesia Respiratory rate DECREASED 5 Endomorphins β R 30 γ H2N α GDP INACTIVE G-PROTEINS EXTRACELLULAR Agonist A R β γ α GTP GDP GTPase P P β R P γ α P GTP INTRACELLULAR HOOC ACTIVATED G-PROTEINS IV. MECHANISM OF ACTION MORPHINE mu receptor G AC i (-) POTASSIUM K+ c-AMP CHANNELS Calcium CALCIUM ENTRY [Ca] BLOCKED i Decreased release of neurotransmitters 6 A. Decrease cyclic AMP 1. mu and delta receptors are coupled to adenylate cyclase (AC) via a G protein (GTP-binding protein) 2. changes in phosphorylation of proteins resulting in decreases in calcium entry. 3. mu and delta receptor activation decreases c-AMP B. Increase potassium efflux 1 1. results in decreased firing of neurons (hyperpolarization). This also decreases calcium entry. 2. All opioid receptor activation increases potassium efflux C. Decreases calcium entry to neurons 2 1. mu, delta, and kappa receptor activation decreases calcium entry 2. blocks release of neurotransmitters since intracellular calcium levels ([Ca]i) levels fall. Opioid peptides hyperpolarize cells to decrease action potential firing Gate Control Theory of Pain from RVM enk projection neuron Glut afferent fiber Sub P V. Pain pathways from Brody et al., 1995 Somatosensory cortex (postcentral gyrus): sensory-discriminative aspects of pain To limbic areas and frontal cortex: arousal, emotional, affective components of pain Intralaminar thalamic nuclear complex Vertebrobasilar thalamic complex Midbrain periaqueductal gray Paleospinothalamic tract (both ascend in anterolater quadrant of spinal cord) Neospinothalamic tract Nucleus raphe magnus in lower brainstem Descending pain-suppressing pathway in dorsolateral funiculus Pain stimulus entering dorsal horn via C and Aδ fiber . 7 VII. CLINICAL EFFECTS A. Summary of clinical responses produced by opioid analgesics: Drug Analgesia Antitussive Constipation Respiratory Abuse morphine +++ ++ +++ +++ +++ heroin +++ ++ +++ +++ ++++ codeine + ++ ++ + ± oxymorphone +++ + ++ +++ +++ meperidine ++ - ± +++ ++ propoxyphene + - ± + + pentazocine ++ - ± + ± butorphanol ++ + ± +++ ± buprenorphine ± + ±±± ++++ (strongest effect); + (weak effect); ± (weak and variable effect); - (no effect) B. Other effects of the opioid analgesics: VIII. CLINICAL SIGNS OF OPIATE OVER- 1. Miosis DOSE 2. Nausea A. Coma 3. Constipation – may be particularly B. Pin-point pupils (miosis) problematic in older people, concomitant use of a C. Respiratory depression stimulant laxative is advised. D. Decreased blood pressure E. Decreased body temperature 4. Histamine release F. Convulsions with some opiates 5. Tolerance and Physical dependence VI. TREATMENT OF OVERDOSE IX. MAINTENANCE OF OPIATE ABSTINENCE A. Naloxone i.v. rapid reversal, but rapid offset. May require repeated A. Methadone administration. 1. long acting mu agonist 2. orally active B. Clonidine - alpha-2 agonist which decreases the release of NE (norepinephrine) and thus, decreases some of B. Ventilate the adrenergic effects of opiate withdrawal C. Naltrexone - oral or long acting depo-injection (experimental) C. Drugs to control hypotension. D. Buprenorphine - “First-line drug”mixed agonist/antagonist, blocks self-administration in opiate addicts, low abuse potential, mild physical dependence. 8 X. WITHDRAWAL FROM OPIATES XI. THERAPEUTIC USES OF A. GENERALLY not life threatening SELECTED OPIATES B. "Flu-like", emesis, diarrhea, chills A. Opiate Agonists C. Due to release of NE and ACh (acetylcholine) 1. Morphine (cont.) 1. Morphine f. also administered by patient-controlled infusion pumps. a. used for severe pain The use of corticosteroids by the patient should be halted for at least 2 weeks prior to the insertion of the catheter to prevent b. duration of action 4-5 hrs infection since morphine increases the immunosuppressive effects of the steroids. c. active i.v. and i.m., and epidurally, LOW activity if given orally ( high "first pass" effect) g.Clearance of morphine depends upon adequate renal function to clear the glucuronidated form of the morphine. The d. elevate head
Load more

Recommended publications
  • Evaluation of in Silico Approach for Prediction of Presence of Opioid Peptides in Wheat
    Evaluation of in silico approach for prediction of presence of opioid peptides in wheat This is the Accepted version of the following publication Garg, Swati, Apostolopoulos, Vasso, Nurgali, Kulmira and Mishra, Vijay Kumar (2018) Evaluation of in silico approach for prediction of presence of opioid peptides in wheat. Journal of Functional Foods, 41. 34 - 40. ISSN 1756-4646 The publisher’s official version can be found at https://www.sciencedirect.com/science/article/pii/S1756464617307454 Note that access to this version may require subscription. Downloaded from VU Research Repository https://vuir.vu.edu.au/36577/ 1 1 Evaluation of in silico approach for prediction of presence of opioid peptides in wheat 2 gluten 3 Abstract 4 Opioid like morphine and codeine are used for the management of pain, but are associated 5 with serious side-effects limiting their use. Wheat gluten proteins were assessed for the 6 presence of opioid peptides on the basis of tyrosine and proline within their sequence. Eleven 7 peptides were identified and occurrence of predicted sequences or their structural motifs were 8 analysed using BIOPEP database and ranked using PeptideRanker. Based on higher peptide 9 ranking, three sequences YPG, YYPG and YIPP were selected for determination of opioid 10 activity by cAMP assay against µ and κ opioid receptors. Three peptides inhibited the 11 production of cAMP to varied degree with EC50 values of YPG, YYPG and YIPP were 5.3 12 mM, 1.5 mM and 2.9 mM for µ-opioid receptor, and 1.9 mM, 1.2 mM and 3.2 mM for κ- 13 opioid receptor, respectively.
    [Show full text]
  • 2019-2020 Award Recipients
    2019-2020 AWARD RECIPIENTS The Office of Undergraduate Research and Creative Activities is pleased to announce the MAYS and RPG recipients for the 2019-2020 academic year. Please join us in congratulating these students and their faculty mentors. Major Academic Year Support (MAYS) Student: Kelly Ackerly Mentor: Dr. Daniel Greenberg Major: Psychology Department: Psychology An Exploration of Maternal Factors Affecting Children’s Autobiographical Memory In day-to-day interactions, mothers and their young children discuss memories of events they have experienced. Research has demonstrated the relationship between these interactions and the development of children’s memories. It is through these interactions that children learn how to interpret personal experiences and develop the skill of talking about them with others in a coherent way. Additionally, studies have found that children are more likely to form false memories—that is, inaccurate “memories” of events that did not actually occur – because their memories are more easily manipulated. In this study, we will explore whether the way mothers talk to their children about ambiguous events affects the children’s interpretations and memories of the event. We will also attempt to determine if there is a relationship between mothers’ negativity during discussions and their child’s formation of false memories. To explore this idea, mothers and their children (aged 3 to 6 years) are given a handful of ambiguous situations to interpret separately. Children are given the opportunity to make slime with a research assistant while a second research assistant acts out ambiguous situations that could have a positive or negative interpretation. The children are evaluated on the way they interpret the situations and whether they form a negative false memory.
    [Show full text]
  • Characterisation and Partial Purification of a Novel Prohormone Processing Enzyme from Ovine Adrenal Medulla
    Volume 246, number 1,2, 44-48 FEB 06940 March 1989 Characterisation and partial purification of a novel prohormone processing enzyme from ovine adrenal medulla N. Tezapsidis and D.C. Parish Biochemistry Group, School of Biological Sciences, University of Sussex, Falmer, Brighton, Sussex, England Received 3 January 1989 An enzymatic activity has been identified which is capable of generating a product chromatographically identical with adrenorphin from the model substrate BAM 12P. This enzyme was purified by gel filtration and ion-exchange chromatog- raphy and characterised as having a molecular mass between 30 and 45 kDa and an acidic pL The enzyme is active at the acid pH expected in the secretory vesicle interior and is inhibited by EDTA, suggesting that it is a metalloprotease. This activity could not be mimicked by incubation with lysosomal fractions and it meets the criteria to be considered as a possible prohormone processing enzyme. Prohormone processing; Adrenorphin; Secretory vesiclepurification 1. INTRODUCTION The purification of an endopeptidase responsi- ble for the generation of adrenorphin was under- Active peptide hormones are released from their taken, using the ovine adrenal medulla as a source. precursors by endoproteolytic cleavage at highly Adrenorphin is known to be located in the adrenal specific sites. The commonest of these is cleavage medulla of all species so far investigated [6]. at pairs of basic residues such as lysine and Secretory vesicles (also known as chromaffin arginine [1,2]. However another common class of granules) were isolated as a preliminary purifica- processing sites are known to be at single arginine tion step, since it is known that prohormone pro- residues, adjacent to a proline [3].
    [Show full text]
  • Opioid Imaging
    529 NEUROIMAGING CLINICS OF NORTH AMERICA Neuroimag Clin N Am 16 (2006) 529–552 Opioid Imaging Alexander Hammers, PhDa,b,c,*, Anne Lingford-Hughes, PhDd,e - Derivation, release, peptide action, Changes in receptor availability in pain and metabolism and discomfort: between-group - Receptors and ligands comparisons Receptors Direct intrasubject comparisons of periods Species differences with pain and pain-free states Regional and layer-specific subtype - Opioid imaging in epilepsy distributions Focal epilepsies Ligands Idiopathic generalized epilepsy - Positron emission tomography imaging Summary of opioid receptors - Opioid imaging in other specialties Introduction PET imaging Movement disorders Quantification of images Dementia Available ligands and their quantification Cardiology - Opioid receptor imaging in healthy - Opioid imaging in psychiatry: addiction volunteers - Summary - Opioid imaging in pain-related studies - Acknowledgments - References Opioids derive their name from the Greek o´pioy agonists provided evidence for the existence of mul- for poppy sap. Various preparations of the opium tiple receptors [4]. In the early 1980s, there was ev- poppy Papaver somniferum have been used for pain idence for the existence of at least three types of relief for centuries. Structure and stereochemistry opiate receptors: m, k, and d [5,6]. A fourth ‘‘orphan’’ are essential for the analgesic actions of morphine receptor (ORL1 or NOP1) displays a high degree and other opiates, leading to the hypothesis of the of structural homology with conventional opioid existence of specific receptors. Receptors were iden- receptors and was identified through homology tified simultaneously by three laboratories in 1973 with the d receptor [7], but the endogenous ligand, [1–3]. The different pharmacologic activity of orphanin FQ/nociceptin, does not interact directly Dr.
    [Show full text]
  • Opioid Peptides 49 Ryszard Przewlocki
    Opioid Peptides 49 Ryszard Przewlocki Abbreviations ACTH Adrenocorticotropic hormone CCK Cholecystokinin CPA Conditioned place aversion CPP Conditioned place preference CRE cAMP response element CREB cAMP response element binding CRF Corticotrophin-releasing factor CSF Cerebrospinal fluid CTAP D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (m-opioid receptor antagonist) DA Dopamine DOP d-opioid peptide EOPs Endogenous opioid peptides ERK Extracellular signal-regulated kinase FSH Follicle-stimulating hormone GnRH Gonadotrophin-releasing hormone HPA axis Hypothalamo-pituitary-adrenal axis KO Knockout KOP k-opioid peptide LH Luteinizing hormone MAPK Mitogen-activated protein kinase MOP m-opioid peptide NOP Nociceptin opioid peptide NTS Nucleus tractus solitarii PAG Periaqueductal gray R. Przewlocki Department of Molecular Neuropharmacology, Institute of Pharmacology, PAS, Krakow, Poland Department of Neurobiology and Neuropsychology, Jagiellonian University, Krakow, Poland e-mail: [email protected] D.W. Pfaff (ed.), Neuroscience in the 21st Century, 1525 DOI 10.1007/978-1-4614-1997-6_54, # Springer Science+Business Media, LLC 2013 1526 R. Przewlocki PDYN Prodynorphin PENK Proenkephalin PNOC Pronociceptin POMC Proopiomelanocortin PTSD Posttraumatic stress disorder PVN Paraventricular nucleus SIA Stress-induced analgesia VTA Ventral tegmental area Brief History of Opioid Peptides and Their Receptors Man has used opium extract from poppy seeds for centuries for both pain relief and recreation. At the beginning of the nineteenth century, Serturmer first isolated the active ingredient of opium and named it morphine after Morpheus, the Greek god of dreams. Fifty years later, morphine was introduced for the treatment of postoper- ative and chronic pain. Like opium, however, morphine was found to be an addictive drug.
    [Show full text]
  • The Role of Protein Convertases in Bigdynorphin and Dynorphin a Metabolic Pathway
    Université de Montréal The Role of Protein Convertases in Bigdynorphin and Dynorphin A Metabolic Pathway par ALBERTO RUIZ ORDUNA Département de biomédecine vétérinaire Faculté de médecine vétérinaire Mémoire présenté à la Faculté de médecine vétérinaire en vue de l’obtention du grade de maître ès sciences (M.Sc.) en sciences vétérinaires option pharmacologie Décembre, 2015 © Alberto Ruiz Orduna, 2015 Résumé Les dynorphines sont des neuropeptides importants avec un rôle central dans la nociception et l’atténuation de la douleur. De nombreux mécanismes régulent les concentrations de dynorphine endogènes, y compris la protéolyse. Les Proprotéines convertases (PC) sont largement exprimées dans le système nerveux central et clivent spécifiquement le C-terminale de couple acides aminés basiques, ou un résidu basique unique. Le contrôle protéolytique des concentrations endogènes de Big Dynorphine (BDyn) et dynorphine A (Dyn A) a un effet important sur la perception de la douleur et le rôle de PC reste à être déterminée. L'objectif de cette étude était de décrypter le rôle de PC1 et PC2 dans le contrôle protéolytique de BDyn et Dyn A avec l'aide de fractions cellulaires de la moelle épinière de type sauvage (WT), PC1 -/+ et PC2 -/+ de souris et par la spectrométrie de masse. Nos résultats démontrent clairement que PC1 et PC2 sont impliquées dans la protéolyse de BDyn et Dyn A avec un rôle plus significatif pour PC1. Le traitement en C-terminal de BDyn génère des fragments peptidiques spécifiques incluant dynorphine 1-19, dynorphine 1-13, dynorphine 1-11 et dynorphine 1-7 et Dyn A génère les fragments dynorphine 1-13, dynorphine 1-11 et dynorphine 1-7.
    [Show full text]
  • 2009-2010 Catalogue Peptide
    2009­2010 Peptide Catalogue Generic Peptides Cosmetic Peptides Catalogue Peptides Designer BioScience Ltd Designer BioScience Table of Contents Ordering Information........................................................................................................................................2 Terms and Conditions.......................................................................................................................................3 Generic Peptides...............................................................................................................................................5 Cosmetic peptides...........................................................................................................................................10 Catalogue Peptides..........................................................................................................................................11 Custom Peptide Synthesis.............................................................................................................................292 Alphabetical Index........................................................................................................................................294 Catalogue Number Index..............................................................................................................................319 Designer BioScience Ltd, St John's Innovation Centre, Cambridge, CB4 0WS, United Kingdom Tel.: +44 (0) 1223 322931 Fax: +44 (0) 808 2801 506 [email protected]
    [Show full text]
  • Endorphin in Feeding and Diet-Induced Obesity
    Neuropsychopharmacology (2015) 40, 2103–2112 © 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org Involvement of Endogenous Enkephalins and β-Endorphin in Feeding and Diet-Induced Obesity ,1 1,2 1 1 Ian A Mendez* , Sean B Ostlund , Nigel T Maidment and Niall P Murphy 1 Hatos Center, Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of 2 California, Los Angeles, Los Angeles, CA, USA; Department of Anesthesiology and Perioperative Care, University of California, Irvine, Irvine, CA, USA Studies implicate opioid transmission in hedonic and metabolic control of feeding, although roles for specific endogenous opioid peptides have barely been addressed. Here, we studied palatable liquid consumption in proenkephalin knockout (PENK KO) and β-endorphin- deficient (BEND KO) mice, and how the body weight of these mice changed during consumption of an energy-dense highly palatable ‘ ’ cafeteria diet . When given access to sucrose solution, PENK KOs exhibited fewer bouts of licking than wild types, even though the length of bouts was similar to that of wild types, a pattern that suggests diminished food motivation. Conversely, BEND KOs did not differ from wild types in the number of licking bouts, even though these bouts were shorter in length, suggesting that they experienced the sucrose as being less palatable. In addition, licking responses in BEND, but not PENK, KO mice were insensitive to shifts in sucrose concentration or hunger. PENK, but not BEND, KOs exhibited lower baseline body weights compared with wild types on chow diet and attenuated weight gain when fed cafeteria diet.
    [Show full text]
  • [Leu ] Enkephalin Enhances Active Avoidance Conditioning in Rats and Mice Patricia H
    NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO. 1 53 [Leu ] Enkephalin Enhances Active Avoidance Conditioning in Rats and Mice Patricia H. Janak, Ph.D., Jennifer J. Manly, and Joe L. Martinez, Jr., Ph.D. The effects of intraperitoneal (IP) administration of the jump-up one-way active avoidance response. When endogenous opioid peptide, [Leu1enkephalin (LE), on administered to Sprague-Dawley rats immediately after avoidance conditioning in rodents were investigated. At a training, LE (30 /lglkg IP) enhanced jump-up avoidance dose of 30 /lglkg (IP), LE enhanced acquisition of a responding at test 24 hours after peptide injection. one-way step-through active avoidance response when Previously, we found LE to impair acquisition in the administered 2 minutes before training to Swiss Webster same tasks in both rats and mice, also at microgram mice. [Leu1enkephalin produced aU-shaped doses, and also in a U-shaped manner. Thus, LE can dose-response function because both lower and higher either enhance or impair learning within the same species doses of LE did not affect avoidance responding. and the same task; these findings are in agreement with fLeu1enkephalin-induced enhancement of avoidance recent theoretical proposals regarding the nature of acquisition was also observed in Sprague-Dawley rats; compounds, such as LE, that modulate learning and the intraperitoneal injection of 10 /lglkg LE, administered memory. [Neuropsychopharmacology 10:53-60, 19941 5 minutes before training, enhanced acquisition of a KEY WORDS: Enkephalin; Aversive conditioning; improve or worsen learning and memory (Martinez et Acquisition; Retention; Learning; Memory; Rat; Mouse al. 1991a; Schulteis et al. 1990; Schulteis and Martinez 1992a; Gold 1989).
    [Show full text]
  • Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions
    Molecular Pharmacology Fast Forward. Published on June 2, 2020 as DOI: 10.1124/mol.120.119388 This article has not been copyedited and formatted. The final version may differ from this version. File name: Opioid peptides v45 Date: 5/28/20 Review for Mol Pharm Special Issue celebrating 50 years of INRC Five decades of research on opioid peptides: Current knowledge and unanswered questions Lloyd D. Fricker1, Elyssa B. Margolis2, Ivone Gomes3, Lakshmi A. Devi3 1Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; E-mail: [email protected] 2Department of Neurology, UCSF Weill Institute for Neurosciences, 675 Nelson Rising Lane, San Francisco, CA 94143, USA; E-mail: [email protected] 3Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, Annenberg Downloaded from Building, One Gustave L. Levy Place, New York, NY 10029, USA; E-mail: [email protected] Running Title: Opioid peptides molpharm.aspetjournals.org Contact info for corresponding author(s): Lloyd Fricker, Ph.D. Department of Molecular Pharmacology Albert Einstein College of Medicine 1300 Morris Park Ave Bronx, NY 10461 Office: 718-430-4225 FAX: 718-430-8922 at ASPET Journals on October 1, 2021 Email: [email protected] Footnotes: The writing of the manuscript was funded in part by NIH grants DA008863 and NS026880 (to LAD) and AA026609 (to EBM). List of nonstandard abbreviations: ACTH Adrenocorticotrophic hormone AgRP Agouti-related peptide (AgRP) α-MSH Alpha-melanocyte stimulating hormone CART Cocaine- and amphetamine-regulated transcript CLIP Corticotropin-like intermediate lobe peptide DAMGO D-Ala2, N-MePhe4, Gly-ol]-enkephalin DOR Delta opioid receptor DPDPE [D-Pen2,D- Pen5]-enkephalin KOR Kappa opioid receptor MOR Mu opioid receptor PDYN Prodynorphin PENK Proenkephalin PET Positron-emission tomography PNOC Pronociceptin POMC Proopiomelanocortin 1 Molecular Pharmacology Fast Forward.
    [Show full text]
  • T-4601 Rabbin Anti Α-Neoendorphin Α-Neoendorphin Is an Endogenous Opioid Neuropeptide with a Decapeptide Structure
    BMA BIOMEDICALS Peninsula Laboratories T-4601 Rabbin anti α-Neoendorphin α-Neoendorphin is an endogenous opioid neuropeptide with a decapeptide structure. It is derived from the proteolytic cleavage of prodynorphin. Some studies revealed that α- Neoendorphin immunoreactive fibers throughout the human brainstem and it can be found in the caudal part of the solitary nucleus, in the caudal and the gelatinosa parts of the spinal trigeminal nucleus, and in the central grey matter of medulla. This antibody was generated by immunization of rabbits with α-Neoendorphin coupled to a carrier protein. TECHNICAL AND ANALYTICAL CHARACTERISTICS Lot number: A03648 Host species: Rabbit IgG Quantity: 400µg Format: Protein A affinity purified from antiserum, lyophilized, packaged under nitrogen. Reconstitute by adding 0.2ml distilled water. This stock solution contains 2mg/ml IgG, phosphate buffer saline pH 7.4 (PBS), and 0.02% (w/v) Thimerosal as a preservative. Stability: Original vial: at least one year at 4º - 8ºC from date of delivery. Minimize repeated thawing and freezing of the antiserum by freezing aliquots at - 20ºC or below. Applications: This antibody has been tested and validated in ELISA against α- Neoendorphin. Other applications like immunohistochemistry (IHC), FACS or Western Blot may work as well. Optimal dilutions should be determined by the end user. Please see www.bma.ch for protocols and general information. Immunogen: Synthetic peptide H-Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro-Lys-OH coupled to carrier protein. BMA BIOMEDICALS, Rheinstrasse
    [Show full text]
  • T-4591 Rabbit Anti Α-Neoendorphin Α-Neoendorphin Is an Endogenous Opioid Neuropeptide with a Decapeptide Structure
    BMA BIOMEDICALS Peninsula Laboratories T-4591 Rabbit anti α-Neoendorphin α-Neoendorphin is an endogenous opioid neuropeptide with a decapeptide structure. It is derived from the proteolytic cleavage of prodynorphin. Some studies revealed that α- Neoendorphin immunoreactive fibers throughout the human brainstem and it can be found in the caudal part of the solitary nucleus, in the caudal and the gelatinosa parts of the spinal trigeminal nucleus, and in the central grey matter of medulla. This antibody was generated by immunization of rabbits with α-Neoendorphin coupled to a carrier protein. TECHNICAL AND ANALYTICAL CHARACTERISTICS Lot number: A09929 Host species: Rabbit IgG Quantity: 50ml Format: This polyclonal antibody is supplied as a lyophilized powder. The powder should be rehydrated with 50ml of RIA buffer. Upon reconstitution to 50ml total volume, the solution contains 0.1M sodium phosphate buffer (pH 7.4), 0.05M NaCl, 0.1% BSA, 0.01% NaN3, and 0.1% Triton X-100. Store at 4° - 8°C. This should ensure antibody stability for approximately one month. Stability: Original vial: at least one year at 4° - 8°C from date of delivery. Minimize repeated thawing and freezing of the antiserum by freezing aliquots at -20°C or below. Applications: This antibody has been tested and validated in ELISA against α- Neoendorphin. Other applications like immunohistochemistry (IHC), FACS or Western Blot may work as well. Optimal dilutions should be determined by the end user. Please see www.bma.ch for protocols and general information. Immunogen: Synthetic peptide H-Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro-Lys-OH coupled to carrier protein.
    [Show full text]